Stockpolly
Search
Delisting risk
MTVA · NASDAQ · Biotechnology

MetaVia (MTVA)

Clinical developer of obesity and MASH therapies.

$1.83
Pre-market−0.01 (−0.56%)
At close$1.84(+6.98%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
4671066443245
Research & development245854222023
222222222222
General & administrative222222222002
Other expenses000000000000
Operating income−4−6−7−10−6−6−4−4−3−2−4−5
000010000000
Interest income000000000000
Other non-operating income0−300−10000000
Income before tax−4−5−7−10−6−5−4−4−3−2−4−5
Net income from continuing operations−4−5−7−10−6−5−4−4−3−2−4−5
Net income−4−5−7−10−6−5−4−4−3−2−4−5
EPS, basic−$8.25−$11.55−$14.52−$20.35−$6.05−$6.60−$3.96−$2.86−$1.54−$0.84−$0.79−$0.90
EPS, diluted−$8.25−$11.55−$14.52−$20.35−$6.05−$6.60−$3.96−$2.86−$1.54−$0.84−$0.79−$0.90
Weighted average shares, basic000011112256
Weighted average shares, diluted000011112256
EBITDA−4−2−7−10−6−5−4−4−3−2−4−5
Depreciation & amortization000000000000
EBIT−4−2−7−10−6−5−4−4−3−2−4−5